GlassScriptPhysician profile
Arthur W Duran
NPI 1588657050
$1,179.39
in general payments reported to CMS, 2019-2025
26 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $978 · 2020: $189 · 2022: $12.94.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $184.88 | 2019-2020 | |
| Pfizer INC. | $164.13 | 2019-2020 | |
| Novo Nordisk INC | $108.33 | 2019 | |
| Abbvie INC. | $87.66 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $63.99 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $62.57 | 2019 | |
| Janssen Pharmaceuticals, INC | $60.47 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $56.21 | 2019 | |
| Merck Sharp & Dohme LLC | $54.19 | 2019-2020 | |
| Amarin Pharma, INC. | $42.72 | 2019 | |
| Novartis Pharmaceuticals Corporation | $38.44 | 2019 | |
| Allergan, INC. | $32.37 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $24.61 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.17 | 2019 | |
| Dermira, INC. | $22.60 | 2019 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $17.95 | 2019 | |
| Abbott Laboratories | $17.01 | 2019 | |
| Astellas Pharma US INC | $16.50 | 2020 | |
| Avanir Pharmaceuticals, INC. | $16.06 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $15.48 | 2019 | |
| Ironshore Pharmaceuticals INC. | $14.16 | 2019 | |
| Nabriva Therapeutics, Plc | $12.83 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $12.65 | 2019 | |
| Ibsa Pharma INC. | $11.20 | 2019 | |
| Glaxosmithkline, LLC. | $10.88 | 2019 | |
| Fidia Pharma USA INC. | $8.33 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arthur Duran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.